• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

A study on mevalonic acid pathway-targeting therapy to recovery osteoclasts damaged with bisphosphonate

Research Project

Project/Area Number 23659957
Research Category

Grant-in-Aid for Challenging Exploratory Research

Allocation TypeMulti-year Fund
Research Field Surgical dentistry
Research InstitutionFukuoka Dental College

Principal Investigator

IKEBE Tetsuro  福岡歯科大学, 口腔歯学部, 教授 (20202913)

Project Period (FY) 2011 – 2012
Project Status Completed (Fiscal Year 2012)
Budget Amount *help
¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2011: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Keywords破骨細胞 / 顎骨壊死 / ビスフォスフォネート / メバロン酸
Research Abstract

Nitrogen-containing bisphosphonate (BP) is used as effective therapeutic agent for managing bone-resorbing diseases such as osteoporosis and cancer bone metastasis. It is well know n that osteonecrosis of the jaw occasionally occurs in the patients treated with nitrogen-containing bisphosphonate after tooth extraction, which is called as BRONJ. Although BRONJ is quite difficult to treat and annoys both the patients and dentists for a long time, any effective therapies for BRONJ have not been established. The target cell of BP is osteoclast. BP inhibits the mevalonic acid pathway of osteoclast to inhibit osteoclastic bone-resorbing activity. In order to recover the BP-induced inhibition of osteoclast activity, the effects of geranylgeraniol (GGOH), an intermediate of mevalonic acid pathway, on BP-induced inhibition of osteoclast activity was investigated in this study. As a result, the addition of GGOH to cultured osteoclasts restored multinucleation, TRAP expression, cell migratinability and the expression of cell fusion-promoting factor STAMP of BP-inhibited osteoclasts. This study suggests that GGOH may neutralize the adverse effects of BP in osteoclasts.

Report

(3 results)
  • 2012 Annual Research Report   Final Research Report ( PDF )
  • 2011 Research-status Report
  • Research Products

    (3 results)

All 2013 2011

All Journal Article (3 results) (of which Peer Reviewed: 1 results)

  • [Journal Article] Pathophysiology of BRONJ:Drug-related osteoclastic disease of the jaw2013

    • Author(s)
      Ikebe T.
    • Journal Title

      (review) Oral Science Int

      Volume: 10 Pages: 1-8

    • Related Report
      2012 Final Research Report
  • [Journal Article] Pathophysiology of BRONJ: Drug-related osteoclastic disease of the jaw.2013

    • Author(s)
      Ikebe T.
    • Journal Title

      Oral Science Int

      Volume: 10 Issue: 1 Pages: 1-8

    • DOI

      10.1016/s1348-8643(12)00045-6

    • Related Report
      2012 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Zoledronic acid inhibits RANK expression and migration of osteoclast precursors during osteoclastogenesis.2011

    • Author(s)
      Kimachi K, Kajiya H, Nakayama S,Ikebe T, Okabe K.
    • Journal Title

      Naunyn-Schmied Arch Pharmacol

      Volume: 383 Pages: 297-308

    • Related Report
      2012 Final Research Report

URL: 

Published: 2011-08-05   Modified: 2019-07-29  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi